Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism

Abstract

Background: The basis for the treatment of hypothyroidism with levothyroxine (LT4) is that humans activate T4 to triiodothyronine (T3). Thus, while normalizing serum TSH, LT4 doses should also restore the body’s reservoir of T3. However, there is evidence that T3 is not fully restored in LT4-treated patients. Summary: For patients that remain symptomatic on LT4 therapy, clinical guidelines recommend, on a trial basis, therapy with LT4+LT3. Reducing the LT4 dose by 25 mcg/day and adding 2.5-7.5 mcg LT3 once or twice a day is an appropriate starting point. Transient episodes of hypertriiodothyroninemia with these doses of LT4 and LT3 are unlikely to go above the reference range and have not been associated with adverse drug reactions (ADRs). Trials following almost a thousand patients for almost one year indicate that similar to LT4, therapy with LT4+LT3 can restore euthyroidism while maintaining a normal serum TSH. An observational study of 400 patients with a mean follow-up of 9 years, do not indicate increased mortality or morbidity risk due to cardiovascular disease, AF, or fractures after adjusting for age when compared to patients taking only LT4. Desiccated thyroid extract (DTE) is a form of combination therapy in which the LT4/LT3 ratio is 4:1; the mean daily dose of DTE needed to normalize serum TSH contains 11 mcg T3, but some patients may require higher doses. DTE remains outside formal FDA oversight, and consistency of T4 and T3 contents is monitored by the manufacturers only. Conclusions: Newly diagnosed hypothyroid patients should be treated with LT4. A trial of combination therapy with LT4+LT3 can be considered for those patients that have unambiguously not benefited from LT4.